AloeVeritas Along with PainSmarts and the GPOSO, Announce Initiation of

Phase I Observational Study Evaluating AloeMD

AloeVeritas along with PainSmarts and GPOSO (Global Professional Observational Study
Organization), Announce Initiation of Phase I Observational Study Evaluating AloeMD for the
relief of pain without Opioids, Steroids, and NSAIDs.

Dallas, TX, April 20, 2018 --(PR.com)-- AloeVeritas today announced the call for consumer volunteers
in a Phase I study of AloeMD, also known as an extracellular matrix protector and pain disruptor.
AloeVeritas is testing AloeMD; a physician created and patented topical application formula, designed
for temporary and long-term natural pain relief from chronic inflammation. And in turn, is advocating and
supporting toxic pain medication abuse awareness.

The Phase I study, conducted in conjunction with Painsmarts, is a strictly volunteer, randomized, study.
The goal of the study is to evaluate the unique active botanical compound efficacy, tolerability and safety
in an alternative pain reliever with volunteers from around the world. The study will take place in the
United States and Europe, and will enroll subjects until the end of the year.

AloeVeritas partnered with patent holder, Dr. Joseph McWherter, and through AloeVeritas worldwide
rights it will study, develop and commercialize specific patented compound combinations for the natural
relief of chronic pain due to inflammation. AloeMD's drug-free formulation containing Dr. McWherter's
patented 100% natural bioceutical matrix is a molecular compound, which targets the extracellular matrix
through a novel mechanism of topical smart absorption delivery technology, allowing the body to
ultimately repair itself, naturally, without the use of toxic chemicals.

"AloeVeritas and PainSmarts share a commitment to advancing natural botanical compounds with the
potential to address the unmet need that exists for consumers experiencing chronic pain with little to no
long-term relief from common pain modalities and limited alternatives to drugs or opioid-based pain
medication," said Christopher Hardy, CEO, AloeVeritas. "Dr. McWherter's leadership in the clinical
development of this product, and work to ensure rapid progress toward the patent approval, has allowed
us to advance this important study. We look forward to our continued collaboration as we move toward
our strategic goal of providing all-natural alternatives, and changing the way consumers view pain relief
in the future.”

About Chronic inflammation and pain

One in every four people worldwide experience chronic inflammation and pain with more than 20 million
Americans between the ages of 20-64 experience debilitating pain. 51% of individuals in pain surveyed
felt they had little or no control over their pain - even when taking prescription medications. Chronic pain
is the number one cause of disability, and addiction or abuse from these pain medications contribute to
the second most abused category of prescription drugs when used for pain management.

About AloeVeritas, US

Page 1/3
PR.com Press Release Distribution Terms of Use
AloeVeritas is a natural wellness company that discovers, develops and commercializes innovative
therapeutics in areas of unmet consumer need through pure aloe Vera based natural cosmeceutical grade
products. The Company's mission is to advance the care and relief of chronic pain sufferers worldwide
and further the study of natural pain relief without the toxic side effects of opioids, steroids, and NSAIDs.
Headquartered in Dallas, Texas, AloeVeritas has operations in North America and Europe and distribute
products through independent sales distributors. A complete suite of wellness products are available
online at www.aloeveritas.com.

About Dr. McWherter

Dr. Joseph McWherter, MD, is an innovative clinical scientist and practicing physician, dedicated to
bringing important new treatments to patients with chronic inflammation, using natural botanical
compounds. Dr. McWherter's proven discovery and clinical development teams have advanced multiple
product candidates with novel mechanisms of action. Dr. McWherter is focused on solutions for the most
challenging problems in chronic pain and inflammation -- with immediate as well as long-term reparative
benefits.

AloeMD, US Patent # 9610258B2 has been determined safe and efficacious in humans for its ultimate
intended use.

For more information on AloeVeritas and PainSmarts, please visit the company's web site at
www.aloeveritas.com or to volunteer as a study participant visit www.painsmarts.org or call
1-833-Tru-Aloe to speak to a customer care representative.

#jointhemovement
#bethemovement

Contact:

Jillian Corley, 1-833-Tru-Aloe (Media)

Chris Hardy, 1-833-Tru-Aloe (Investors)

Source: AloeVeritas, US

Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
AloeVeritas Americas, LLC
Jillian Corley
833-TRU-ALOE
Contact via Email
www.aloeveritas.com

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/751430

News Image:

Page 3/3
PR.com Press Release Distribution Terms of Use